Boundless Bio, Inc., originally founded on April 10, 2018 as Pretzel Therapeutics, Inc., is a Delaware corporation. On July 8, 2019, the company changed its name to Boundless Bio, Inc. They are a clinical-stage oncology company dedicated to unlocking new approaches to cancer therapy, addressing the significant unmet need for oncogene amplification in tumor patients by targeting dyed in vitro DNA (ecDNA), with the root cause of oncogene amplification observed in more than 14% of cancer patients. Their mission is to become a leading biopharmaceutical company, leveraging ecDNA biology to deliver transformative treatments that improve and prolong the lives of patients with previously refractory oncogene-amplified cancer. 

BOLD

BOLD Profile